Cargando…
Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
Somatostatin receptor 2 (SSTR2) has been shown to be expressed in a subset of neuroendocrine tumors and carcinomas and plays a role in imaging studies and guiding therapy. Patients with tumors expressing SSTR2 may be successfully treated with somatostatin inhibitors or radiolabeled somatostatin anal...
Autores principales: | Roden, Anja C., Rakshit, Sagar, Johnson, Geoffrey B., Jenkins, Sarah M., Mansfield, Aaron S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859934/ https://www.ncbi.nlm.nih.gov/pubmed/35198446 http://dx.doi.org/10.3389/fonc.2022.823667 |
Ejemplares similares
-
The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in Localizing Ectopic ACTH Producing Tumors
por: Gözde Özkan, Zeynep, et al.
Publicado: (2013) -
(68)Ga-DOTATATE PET/CT versus (111)In-octreotide
scintigraphy in patients with neuroendocrine tumors: a prospective
study
por: Cavicchioli, Marcelo, et al.
Publicado: (2022) -
Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023) -
Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan
por: Mullangi, Sanjana, et al.
Publicado: (2021) -
Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET/CT
por: Hou, Jiale, et al.
Publicado: (2021)